NTHI
NeOnc Technologies Holdings, Inc. Common StockNTHI
NTHI
–
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for NTHI.
Financial journalist opinion
Based on 4 articles about NTHI published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
WESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100™) for the treatment of pediatric-type diffuse high-grade gliomas, a serious and life-threatening condition affecting children and adolescents.
Neutral
GlobeNewsWire
5 days ago
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc's clinical trial capabilities in India, facilitating the advancement of its development-stage neuro-oncology treatment.
Neutral
GlobeNewsWire
1 week ago
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
Delshad adds broad management and financial expertise to the NeOnc team Delshad adds broad management and financial expertise to the NeOnc team
Neutral
GlobeNewsWire
1 week ago
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team
Neutral
Seeking Alpha
2 months ago
U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings
Two small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on the calendar, some large names in the pipeline could launch in the week ahead.
Neutral
GlobeNewsWire
5 months ago
NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024
NeOnc's Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook NeOnc's Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook
Neutral
GlobeNewsWire
7 months ago
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
WESTLAKE VILLAGE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has begun patient enrollment for the Phase 2 clinical trial of NEO100-02™, the company's first of two drug candidates proceeding through four concurrent clinical trials for various indications and patient populations.
Neutral
GlobeNewsWire
8 months ago
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
WESTLAKE VILLAGE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, received FDA approval to expand its ongoing NEO100-01™ Phase 2a clinical trial to include Recurrent Grade III Astrocytoma with Isocitrate Dehydrogenase 1 (IDH1) mutation.
Neutral
GlobeNewsWire
9 months ago
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
WESTLAKE VILLAGE, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has completed a $18.5 million financing to support the ongoing development and Phase I and II clinical studies of its novel drug and delivery methods designed to address the persistent challenges with overcoming the blood-brain barrier.
Neutral
GlobeNewsWire
10 months ago
NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award
Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases
Charts implemented using Lightweight Charts™